CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
Stock Information for CytoSorbents Corporation
Loading
Please wait while we load your information from QuoteMedia.